Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Alerts About Adverse Effects Of Antidepressants Including GSK’s Paxil

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare May 8 alerted physicians and patients on possible adverse effects of antidepressants. The drugs mentioned by the ministry include Paxil (paroxetine), Luvox/Depromel (fluvoxamine), Toledomin (milnacipran) and Zoloft (sertraline). The Ministry received 268 reports of aggressive behavior after taking the drugs, and actual damage occurred in 35 cases. A casual relation cannot be denied in four cases, according to MHLW. GlaxoSmithKline's Paxil accounts for half of selective serotonin reuptake inhibitors marketed in Japan, and since it was launched in 2000, roughly 1 million patients have taken the drug in Japan. The Japan Society of Mood Disorders has established a committee to raise public attention on the appropriate use of antidepressants. (Click here for more - Japanese language

You may also be interested in...

Industry Delighted By ‘Fixed’ USMCA

Industry associations in the US and Canada have welcomed revisions to the proposed US-Mexico-Canada trade agreement that remove potentially damaging provisions around biologic data exclusivity and include measures favorable to generics, including incentives for generic competition.

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts